Evelo Biosciences, Inc. (NASDAQ:EVLO) Q2 2020 Earnings Conference Call - Final Transcript
Jul 30, 2020 • 08:30 am ET
on enrolling additional individuals with triple-negative breast cancer in our ongoing Phase 1/2 trial and expect to report additional data from this cohort in the fourth quarter of 2020.
Let me now turn the call back over to Simba.
Thank you, Duncan. I want to conclude with a reminder of the upcoming milestones across our portfolio, beginning with EDP1815. We expect data from the Phase 2 trial with ruptures in COVID-19 in the fourth quarter of this year 2020. For the Phase 2/3 TACTIC-E trial, we expect interim safety data and futility analysis in the fourth quarter of this year. We also expect to initiate a Phase 2 trial of EDP1815 in moderate psoriasis in the third quarter of this year with data by mid-2021. We didn't spend time discussing today the additional trials that we're looking to initiate with EDP1815 in atopic dermatitis, a Phase 1b trial in the fourth quarter of this year, as well as our first non-live product candidate for inflammatory diseases, EDP1867, in atopic dermatitis in the first quarter of 2021. Data from these trials are expected in the first quarter and mid-2021, respectively. We plan to provide more detail on the unmet need in atopic dermatitis on our third quarter call in October. Finally, we expect to report additional data from our Phase 1/2 clinical trial of EDP1503 in triple-negative breast cancer in the fourth quarter of this year.
Following our follow-on offering in June and the drawdown of an additional $10 million under our existing debt facility in July, we have sufficient capital to support our operations into the third quarter of 2021, beyond four key clinical milestones for each of our ongoing programs, while enabling continued investment in our platform.
Our lead programs, EDP1815 for psoriasis and COVID-19 and EDP1503 for triple-negative breast cancer have shown promising potential in key areas of unmet medical need, where the potential unique activity of our product candidates may prove particularly beneficial. Over the next six to 12 months, we expect six clinical readouts, which could further validate our platform, reinforce the predictability of our preclinical models, highlight the potential breadth of SINTAX as a drug target across a broad array of programs and enable the further expansion of our efforts into other indications where we may be able to provide transformative results. Alongside the progress of our current pipeline, we've expanded discovery into other disease areas, such as neuroinflammatory disorders, metabolic dysfunction, viral-related inflammatory syndromes and for vaccination.
In closing, I'd like to thank the team at Evelo. Because of their exceptional work, we've been able to continue to deliver on our commitments during the COVID-19 pandemic. We look forward to updating you again soon.
And I'd like to now turn the call over to the operator for questions.